Cat. No.: HY-N0429

Diosbulbin B

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

Purity: 99.88%
CAS No.: 20086-06-0
Formula: C₁₉H₂₀O₆
Molecular Weight:344.36

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Diosbulbin B Chemical Structure

CAS No.: 20086-06-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Bcl-2 Family Isoforms :

All CDK Isoforms :

In Vitro

Diosbulbin B (0.5-400 μM, 24-72 h) inhibits proliferation in A549 and PC-9 cells, with IC₅₀ values of 44.61 and 22.78 μM, respectively^[1].
Diosbulbin B (12.5-100 μM, 24 h) enhances the ratio of cells in the G0/G1 phase in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) induces apoptosis in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) inhibits colony formation in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) reduces the levels of YY1 and apoptosis-related proteins and increases p53 levels in A549 and PC-9 cells^[1].
Diosbulbin B (50-200 μM, 48h) induces autophagy and apoptosis in L-02 hepatocytes^[3].
Diosbulbin B (50-200 μM, 48 h) causes mitochondrial dysfunction in L-02 hepatocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

A549 and PC-9 cells
Concentration:

12.5, 25, 50 and 100 μM
Incubation Time:

24 h
Result:

Markedly enhanced the ratio of cells in the G0/G1 phase.
Decreased the proportion of cells in the S phase and G2/M phase.

Western Blot Analysis^[1]

Cell Line:

A549 and PC-9 cells
Concentration:

12.5, 25, 50 and 100 μM
Incubation Time:

48 h
Result:

Reduced the level of YY1 protein and increased p53 levels.
Suppressed the expression of Cyclin A2 and B2, along with the CDK1, CDK2, CDK4 and BCL-2.

Western Blot Analysis^[3]

Cell Line:

L-02 hepatocytes
Concentration:

50, 100 and 200 μM
Incubation Time:

48 h
Result:

Increased LC3 II/I and Beclin-1 levels and decreased P62 levels.
Enhanced protein expression of Bax and up-regulated activities of caspase-3 and caspase-9.

In Vivo

Diosbulbin B (5-15 mg/kg, i.p., daily for 2 weeks) inhibits tumor growth in xenograft A549 tumor mice models^[1].
Diosbulbin B (16-64 mg/kg, i.g., daily for 12 days) induces liver injury in ICR mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Xenograft A549 tumor mice models^[1]
Dosage:

5 and 15 mg/kg
Administration:

Intraperitoneally injection, daily for 2 weeks
Result:

Reduced tumor volume and weight.
Did not result in any alterations in both body weight and organ coefficient.
Induced tumor cells disorganized and underwent apoptosis.
Reduced the level of YY1 protein and increased p53 levels.
Suppressed the expression of Cyclin A2 and B2, along with the CDK1, CDK2, and CDK4.

Animal Model:

ICR mice (male, 18-22 g)^[2]
Dosage:

16, 32 and 64 mg/kg
Administration:

Orally gavage, daily for 12 days
Result:

Increased the values of ALT, AST, ALP and MDA.
Lost normal architecture inliver.
Reduced glutathione levels and GST, GPx, SOD and CAT activities.

Chemical Information

CAS No. 20086-06-0
Appearance Solid
Molecular Weight 344.36
Formula C₁₉H₂₀O₆
Color White to off-white
SMILES

O=C1[C@]23C[C@H](O1)[C@]4([H])[C@H]5C[C@H](OC5=O)C[C@@]4([H])[C@]2(C)C[C@H](C6=COC=C6)O3
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Medicine

Prediction of network pharmacology, molecular docking-based strategy, and vitro assays to determine potential pharmacological mechanism of Dioscoreae bulbiferae and Bruceae fructus against laryngocarcinoma. [Abstract]

2023 Dec 22;102(51):e36771. PMID: 38134081

Solvent & Solubility

In Vitro:

DMSO : 14.29 mg/mL (41.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9039 mL

14.5197 mL

29.0394 mL

5 mM

0.5808 mL

2.9039 mL

5.8079 mL

10 mM

0.2904 mL

1.4520 mL

2.9039 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.33 mg/mL (3.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.33 mg/mL (3.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.33 mg/mL (3.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhao JQ, et al. The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis. Phytomedicine. 2024 Jul 25;130:155734. [Content Brief]

[2]. Ma Y, et al. Diosbulbin B-induced liver injury in mice and its mechanism. Hum Exp Toxicol. 2014 Jul;33(7):729-36. [Content Brief]

[3]. Ye J, et al. Diosbulbin B-Induced Mitochondria-Dependent Apoptosis in L-02 Hepatocytes is Regulated by Reactive Oxygen Species-Mediated Autophagy. Front Pharmacol. 2019 Jun 19;10:676. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9039 mL	14.5197 mL	29.0394 mL	72.5984 mL
	5 mM	0.5808 mL	2.9039 mL	5.8079 mL	14.5197 mL
	10 mM	0.2904 mL	1.4520 mL	2.9039 mL	7.2598 mL
	15 mM	0.1936 mL	0.9680 mL	1.9360 mL	4.8399 mL
	20 mM	0.1452 mL	0.7260 mL	1.4520 mL	3.6299 mL
	25 mM	0.1162 mL	0.5808 mL	1.1616 mL	2.9039 mL
	30 mM	0.0968 mL	0.4840 mL	0.9680 mL	2.4199 mL
	40 mM	0.0726 mL	0.3630 mL	0.7260 mL	1.8150 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Diosbulbin B

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Diosbulbin B

All Bcl-2 Family Isoforms

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Diosbulbin B Related Classifications

Cat. No.: HY-N0429